Comparative Pharmacology
Head-to-head clinical analysis: MICROSUL versus SULLA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MICROSUL versus SULLA.
MICROSUL vs SULLA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MICROSUL inhibits bacterial dihydropteroate synthase, preventing folate synthesis, and also acts as a competitive antagonist of para-aminobenzoic acid (PABA).
SULLA (sulfamethoxazole/trimethoprim) inhibits bacterial dihydropteroate synthase and dihydrofolate reductase, sequentially blocking folate synthesis and thereby nucleic acid production.
Adult: 160 mg/800 mg (trimethoprim/sulfamethoxazole) orally every 12 hours for 14 days; intravenous dosing: 8-10 mg/kg/day (as trimethoprim) divided every 6, 8, or 12 hours.
100 mg orally once daily, increased to 200 mg daily if needed.
None Documented
None Documented
Terminal elimination half-life: 24-36 hours; prolonged in renal impairment
6-12 hours; prolonged in renal impairment (up to 30 hours)
Renal: 70% unchanged; biliary/fecal: 30% as metabolites
Renal: 70-90% unchanged; biliary/fecal: 5-10%
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic